Get the Stockscreener App
8.56
0.71%
0.06
After Hours:
8.56
Abivax Adr stock is traded at $8.56, with a volume of 71,783.
It is up +0.71% in the last 24 hours and down -16.89% over the past month.
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. They are evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two most common forms are UC and CD.
See More
Previous Close:
$8.50
Open:
$8.45
24h Volume:
71,783
Relative Volume:
0.59
Market Cap:
$534.80M
Revenue:
-
Net Income/Loss:
$-159.39M
P/E Ratio:
-
EPS:
-
Net Cash Flow:
$-105.22M
1W Performance:
-3.39%
1M Performance:
-16.89%
6M Performance:
-38.24%
1Y Performance:
-14.14%
1-Day Range:
$8.39
$8.785
1-Week Range:
$8.23
$9.08
52-Week Range:
$8.23
$17.02
Abivax Adr Stock (ABVX) Company Profile
Compare ABVX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABVX
Abivax Adr
|
8.56 | 534.80M | 0 | -159.39M | -105.22M | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
464.56 | 119.70B | 10.63B | -479.80M | -1.35B | 13.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
754.87 | 82.75B | 13.85B | 4.65B | 3.32B | 35.06 |
|
ARGX
Argen X Se Adr
|
614.59 | 36.73B | 1.86B | -40.29M | -1.28B | -4.16 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.74 | 32.53B | 2.09B | -332.26M | 16.06M | -4.14 |
|
BNTX
Biontech Se Adr
|
120.72 | 28.50B | 3.30B | -501.07M | 1.03B | 11.54 |
Abivax Adr Stock (ABVX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-29-24 | Initiated | Laidlaw | Buy |
| May-20-24 | Initiated | BTIG Research | Buy |
| Apr-29-24 | Initiated | Guggenheim | Buy |
| Apr-29-24 | Initiated | Piper Sandler | Overweight |
| Nov-14-23 | Initiated | Leerink Partners | Outperform |
| Nov-14-23 | Initiated | Morgan Stanley | Equal-Weight |
View All
Abivax Adr Stock (ABVX) Latest News
Abivax Initiates $150 Million ATM Program on Nasdaq - TipRanks
Abivax Reports Strong Q3 Financials and Clinical Progress - TipRanks
Check Out Abivax ADR (ABVX)’s Trade Data Rather Than the Analysts’ Views - SETE News
Insider’s View: Deciphering Abivax ADR (ABVX)’s Financial Health Through Ratios - The Dwinnex
Abivax Congratulates Victor Ambros and Gary Ruvkun on Their Nobel Prize for the Discovery of microRNA and its Role in Post-Transcriptional Gene Regulation - GlobeNewswire Inc.
Abivax SA Unveils New Ulcerative Colitis Treatment Data - TipRanks
Abivax Reports Progress in Ulcerative Colitis Therapy - TipRanks
DEADLINE ALERT for ABR, FIVE, DXC, and INDV: The Law - GlobeNewswire
Wall Street Analysts Believe Abivax SA Sponsored ADR (ABVX) Could Rally 193.62%: Here's is How to Trade - MSN
Is Abivax SA Sponsored ADR (ABVX) Outperforming Other Medical Stocks This Year? - Yahoo Finance
Abivax SA Details Financial Struggles and Advances - TipRanks
Abivax SA Reveals Soaring R&D Costs in H1 2024 - TipRanks
Inflammatory Bowel Disease Treatment Market Size Expected to Reach USD 33.19 Bn by 2032 - GlobeNewswire Inc.
Abivax SA Advances with Positive Trial OutcomesTipRanks.com - TipRanks
Abivax SA Announces Upcoming General MeetingTipRanks.com - TipRanks
Guggenheim starts Abivax stock with Buy, cites promising ulcerative colitis drug By Investing.com - Investing.com
Abivax ADR receives Investment Bank Analyst Rating Update By Investing.com - Investing.com
Abivax SA Secures Funding and Expands Operations - TipRanks
Abivax Adr Stock (ABVX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.35%
0.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):